Grape Seed Powder and Vitamin C Supplementation for Liver Disease (Acquired Hepatic Jaundice)

Impact of Grape (VITIS VINIFERA) Seed Powder Along With Vitamin C Supplementation on Serum Bilirubin Levels in Patients With Acquired Hepatic Jaundice

Jaundice is a frequent medical problem that affects people of all ages. It is important to note that jaundice is not an actual sickness as such itself but rather a symptom of liver illness brought on by an increase in the quantity of bilirubin circulating in the blood owing to improper metabolism and excretion in the urine. The aim of this investigation is to investigate the impact of grape (Vitis Vinifera) seed powder along with vitamin C supplementation on serum bilirubin levels in patients with acquired hepatic jaundice. In addition, it's the first research of its kind to investigate the aforementioned function of grape seed extract with vitamin C in healthy individuals specifically.

According to my study, the division of patients was done between two groups: one was named as Conventional group (CG) and other was named as Intervention group (IG). The conventional treatment group received only conventional medication and intervention group was given Grape-C capsule with dose of one tablet per day for 4 weeks after lunch along with conventional medication. Grape-C capsule continued for 4 weeks and the data was obtained at the initiation and at end of intervention (after 4th week).

According to my research study results the intervention group had a significant decrease in bilirubin levels, ALT, AST, ALP and increase the albumin and gamma glutamyl transferase (GGT) compared to the conventional group. The p-values for the comparison between pre and post intervention levels were highly significant rather than the conventional groups indicating a statistically significant difference.

Inclusion Criteria:

• Both men and women
• Participants between the ages of 20-40 years will be included
• Patients having signs and symptoms of acquired hepatic jaundice
• Patients having high serum bilirubin, albumin, ALT, AST, ALP levels
• The patient having ALT level more than 10-50 U/L were included
• The participants having AST level above than 0-40 IU/L were included in this study
• Patients having ALP level more than 30 - 130 U/L were included in this research study
• Patients having level of bilirubin above than 0 - 21 μmol/L were included in this investigation
• Participants having the range of albumin more than 30-50 g/L were included in this research
• Participants those were underweighted were included

Exclusion Criteria:

• Patients who already taking any supplement or medication
• Participants taking any anti-inflammatory medications
• People who were suffering from any other disease
• Patients who have any known allergies
• Non willing patients
• Lactating women
• Pregnant women
• Smokers